RO-7507062

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameRO-7507062

Drug Alias NameRO7507062RO-7507062RG-6382

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLupus Erythematosus, Systemic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwanPolandThailand +[13]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesF. Hoffmann-La Roche Ag

China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche Ltd

Inactive CompaniesN/A

Active IndicationsLupus Erythematosus, Systemic

Inactive IndicationsN/A

Other Information

ATC CodeN/A